読み込み中
NASDAQHealthcareBiotechnology
最新データ
$23.9798
−$0.1902 · -0.79%
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
通常取引
$23.9798
−$0.1902 · -0.79%
日中の時刻はETです。市場データは遅延する場合があります。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日中レンジ
現在 $23.9798
52週レンジ
現在 $23.9798
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
79
割安
センチメント
55
まちまち
リスク
43
やや高いリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日中レンジ
現在 $23.9798
52週レンジ
現在 $23.9798
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$38.33
上昇余地（59.84%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Core S&P Small-Cap ETFIJR1.65億0.16%1042.94億 USD0.06%$136.96-0.09%
Vanguard Morningstar Total Stock Market ETFVTI8568.37万0.00%2.3兆 USD0.03%$379.2-0.48%
State Street SPDR S&P Biotech ETFXBI7502.83万0.74%100.75億 USD0.35%$148.48-1.16%
iShares Russell 2000 ETFIWM7254.27万0.09%785.63億 USD0.19%$277.11-0.21%
Vanguard Extended Market ETFVXF3171.97万0.03%954億 USD0.05%$232.54-0.41%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2589.15万0.16%160.11億 USD0.03%$53.245-0.07%
iShares Russell 2000 Growth ETFIWO2587.31万0.18%142.49億 USD0.24%$352.78-0.73%
iShares Biotechnology ETFIBB2000.72万0.19%104.01億 USD0.44%$199.19-2.04%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
